Amgen starts $1B Puerto Rico site expansion
USA-based Amgen, the world's largest biotechnology company, says that it expects to invest $1.0 billion over the next four years to expand its manufacturing capacity in Puerto Rico to meet rising global demand for its leading anti-infectives Neulasta (pegfilgrastim) and Neupogen (filgrastim), as well as its anemia drugs Aranesp (darbepoetin) and Epogen (epoetin alfa).
According to the California-headquartered firm, the investment will involve the expansion of its existing facilities in the manufacturing complex in Juncos, Puerto Rico, and the construction of a new formulation, fill and finish facility. By 2010, Amgen expects to have added 500 staff members to its local workforce.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze